Učitavanje...

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks

AIMS/INTRODUCTION: The efficacy and safety of sitagliptin, a highly selective dipeptidyl peptidase‐4 inhibitor, when added to metformin monotherapy was examined in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: In this 52‐week, add‐on to metformin study, 149 patients were randomly as...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kadowaki, Takashi, Tajima, Naoko, Odawara, Masato, Nishii, Mikio, Taniguchi, Tadaaki, Ferreira, Juan Camilo Arjona
Format: Artigo
Jezik:Inglês
Izdano: Wiley-Blackwell 2012
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4019272/
https://ncbi.nlm.nih.gov/pubmed/24843649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12001
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!